PVCT News and Press, Provectus Biopharmaceuticals Inc From 01/09/23

KNOXVILLE, TN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that it had issued a beginning-of-the-year letter for 2023 to the Company’s stockholders, which may be found below. 2023 Letter to Stockholders Dear Provectus Stockholders, ...

KNOXVILLE, TN, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company’s Board of Directors (Board) has decided to not undertake the reverse stock split and authorized share reduction, which Provectus stockholders approved at the Company’s 2022 Ann...

50% CR and 83% ORR by RECIST 1.1 criteria Rapid CRs achieved within 15 to 27 weeks Median PFS not reached during 2-year treatment interval; 83% PFS rate 100% OS rate for CRs; ongoing after 18 to 36 months of study follow-up KNOXVILLE, TN, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Provec...

KNOXVILLE, TN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company’s ongoing, multi-cohort, Phase 1b/2 study of the combination therapy of cancer immunotherapy PV-10, an intratumoral formulation of Provectus’ small molecule rose...

KNOXVILLE, TN, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) has selected “rose bengal sodium” (RBS) for the nonproprietary name of the Company...

KNOXVILLE, TN, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has expanded its sponsored research program with James G. Krueger, MD, PhD , Co-director, Center for Clinical and Translational Science, D. Martin Carter Professor in Clinical Inves...

KNOXVILLE, TN, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Amina El Ayadi, PhD, Assistant Professor, Surgical Sciences Division and Jayson Jay, PhD, Postdoctoral Research Fellow and Jeane B. ...

Provectus ( OTC:PVCT ) said it signed an option agreement with the University of Miami (UM) for an exclusive worldwide license of intellectual property (IP) of a photodynamic antimicrobial therapy (PDAT) medical device. Provectus intends to use the IP — developed by...

KNOXVILLE, TN, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has entered into an option agreement with the University of Miami (UM) for an exclusive worldwide license of intellectual property developed by the Ophthalmic Biophysics Center (OBC) o...

Provectus ( OTC:PVCT ) said it had expanded its sponsored research program with Michio Kurosu, Professor at the University of Tennessee Health Science Center to investigate its pharmaceutical-grade rose bengal to treat anti-fungal and anti-oral bacterial infections. The Kurosu...